Treatment of Patients With KRAS Wild Type Advanced Colorectal Cancer (CRC) With 5-Fluorouracil (5-FU) or 5- FU Plus an Epidermal Growth Factor Receptor (EGFR) Inhibitor (Cetuximab) Based on a Comprehensive Geriatric Assessment (CGA).

Trial Profile

Treatment of Patients With KRAS Wild Type Advanced Colorectal Cancer (CRC) With 5-Fluorouracil (5-FU) or 5- FU Plus an Epidermal Growth Factor Receptor (EGFR) Inhibitor (Cetuximab) Based on a Comprehensive Geriatric Assessment (CGA).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Nov 2017 This study has been completed in Belgium as per European Clinical Trials Database.
    • 01 May 2016 This Trial was completed in Italy.
    • 27 Jan 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top